Metabolic interactions of AGE inhibitor pyridoxamine and antioxidant α-lipoic acid following 22 weeks of treatment in obese Zucker rats

Life Sciences

Volumn 84, Issue 15-16, 2009, Pages 563-568

  Muellenbach, Elizabeth M ^a   Diehl, Cody J ^a   Teachey, Mary K ^a   Lindborg, Katherine A ^a   Hasselwander, Oliver ^b   Matuschek, Markus ^b   Henriksen, Erik J ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b BASF SE   (Germany)

Author keywords

Insulin resistance; Oxidative stress; Skeletal muscle

Indexed keywords

CARBONYL DERIVATIVE; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; PROPYLHEXEDRINE; PROTEIN KINASE B; PYRIDOXAMINE; THIOCTIC ACID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; NONHUMAN; OBESITY; OXIDATIVE STRESS; RAT; SKELETAL MUSCLE; ZUCKER RAT;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; DRUG SYNERGISM; FEMALE; GLUCOSE TOLERANCE TEST; GLYCOSYLATION END PRODUCTS, ADVANCED; INSULIN RESISTANCE; MUSCLE, SKELETAL; OBESITY; OXIDATIVE STRESS; PYRIDOXAMINE; RATS; RATS, ZUCKER; THIOCTIC ACID;

RATTUS;

EID: 62749098225     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.01.021     Document Type: Article

References (32)

1. Alderson N.L., Chachich M.E., Youssef N.N., Beattie R.J., Nachtigal M., Thorpe S.R., and Baynes J.W. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney International 63 (2003) 2123-2133
2. Bloch-Damti A., and Bashan N. Proposed mechanisms for the induction of insulin resistance by oxidative stress. Antioxidant Redox Signaling 7 (2005) 1553-1567
3. Cortez M.Y., Torgan C.E., Brozinick J.T., and Ivy J.L. Insulin resistance of obese Zucker rats exercise trained at two different intensities. American Journal of Physiology Endocrinology and Metabolism 261 (1991) E613-E619
4. DeFronzo R.A., and Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 (1991) 173-194
5. Denton R.M., and Randle P.J. Concentration of glycerides and phospholipids in rat heart and gastrocnemius muscles: effects of alloxan-diabetes and perfusion. Biochemical Journal 104 (1967) 416-422
6. Dokken B.B., Sloniger J.A., and Henriksen E.J. Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in pre-diabetic insulin-resistant rat skeletal muscle. American Journal of Physiology Endocrinology and Metabolism 288 (2005) E1188-E1194
7. Evans J.L., Goldfine I.D., Maddux B.A., and Grodsky G.M. Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction?. Diabetes 52 (2003) 1-8
8. Folch J., Lees M., and Sloane Stanley J.H. A simple method for the isolation and purification of total lipids from animal tissues. Journal of Biological Chemistry 226 (1957) 497-509
9. Frayn K.N., and Maycock P.F. Skeletal muscle triacylglycerol in the rat: methods for sampling and measurement, and studies of biological variability. Journal of Lipid Research 21 (1980) 139-144
10. Han D., Hamilton R.T., Lam P.Y., and Packer L. Modulation of cellular redox and metabolic status by lipoic acid. In: Patel M., and Packer L.P. (Eds). Lipoic Acid. Energy Production, Antioxidant Activity and Health Effects (2008), CRC Press, Boca Raton, FL 293-314
11. Hansen P.A., Gulve E.A., and Holloszy J.O. Suitability of 2-deoxyglucose for in vitro measurement of glucose transport activity in skeletal muscle. Journal of Applied Physiology 76 (1994) 979-985
12. Haramaki N., Han D., Handelman G.J., Tritschler H.J., and Packer L. Cytosolic and mitochondrial systems for NADH- and NADPH-dependent reduction of α-lipoic acid. Free Radical Biology and Medicine 22 (1997) 535-542
13. Hayden M.R., Stump C.S., and Sowers J.R. Introduction: organ involvement in the cardiometabolic syndrome. Journal of the Cardiometabolic Syndrome 1 (2006) 16-24
14. Henriksen E.J. Oxidative stress and antioxidant treatment: effects on muscle glucose transport in animal models of type 1 and type 2 diabetes. In: Packer L.P., Rösen P., Tritschler H.J., King G.L., and Azzi A. (Eds). Antioxidants in Diabetes Management (2000), Marcel Dekker, New York, NY 303-318
15. Henriksen E.J. Exercise training and the antioxidant alpha-lipoic acid in the treatment of insulin resistance and type 2 diabetes. Free Radical Biology and Medicine 40 (2006) 3-12
16. Henriksen E.J. Effects of conjugated linoleic acid and lipoic acid on insulin action in the obese Zucker rat. In: Packer L., and Sies H. (Eds). Oxidative Stress and Inflammatory Mechanisms in Obesity, Diabetes, and the Metabolic Syndrome (2007), CRC Press, Boca Raton, FL 289-299
17. Henriksen E.J., and Dokken B.B. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Current Drug Targets 7 (2006) 1435-1442
18. Henriksen E.J., and Jacob S. Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism 44 (1995) 267-272
19. Jones D.P. Radical-free biology of oxidative stress. American Journal of Physiology Cell Physiology 295 (2008) C849-C868
20. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
21. Metz T.O., Alderson N.L., Chachich M.E., Thorpe S.R., and Baynes J.W. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo. Evidence on the role of lipids in chemical modification of proteins and development of diabetic complications. Journal of Biological Chemistry 278 (2003) 42012-42019
22. Metz T.O., Alderson N.L., Thorpe S.R., and Baynes J.W. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Archives of Biochemistry and Biophysics 419 (2003) 41-49
23. Moini H., Packer L., and Sarna N.E. Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid. Toxicology and Applied Pharmacology 182 (2002) 84-90
24. Muellenbach E.M., Diehl C.J., Teachey M.K., Lindborg K.A., Archuleta T.L., Harrell N.B., Andersen G., Somoza V., Hasselwander O., Matuschek M., and Henriksen E.J. Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant α-lipoic acid on insulin resistance of the obese Zucker rat. Metabolism 57 (2008) 1465-1472
25. Ort T., Gewien R., Lindborg K.A., Diehl C.J., Lemieux A.M., Eisner A., and Henriksen E.J. Alterations in soleus muscle gene expression associated with a metabolic endpoint following exercise training by lean and obese Zucker rats. Physiological Genomics 29 (2007) 302-311
26. Packer L., Witt E.H., and Tritschler H.J. α-Lipoic acid as a biological antioxidant. Free Radical Biology and Medicine 19 (1995) 227-250
27. Reznick A.Z., and Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods in Enzymology 233 (1994) 357-363
28. Stitt A., Gardiner T.A., Alderson N.L., Canning P., Frizzell N., Duffy N., Boyle C., Januszewski A.S., Chachich M., Baynes J.W., and Thorpe S.R. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51 (2002) 2826-2832
29. Streeper R.S., Henriksen E.J., Jacob S., Hokama J.Y., Fogt D.L., and Tritschler H.J. Differential effects of lipoic acid stereoisomers on glucose metabolism in insulin-resistant skeletal muscle. American Journal of Physiology Endocrinology and Metabolism 273 (1997) E185-E191
30. Voziyan P.A., and Hudson B.G. Review: pyridoxamine is a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Molecular Life Science 62 (2005) 1671-1681
31. Yu C., Chen Y., Cline G.W., Zhang D., Zong H., Wang Y., Bergeron R., Kim J.K., Cushman S.W., Cooney G.J., Atcheson B., White M.F., Kraegen E.W., and Shulman G.I. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. Journal of Biological Chemistry 277 (2002) 50230-50236
32. Zierath J.R., Krook A., and Wallberg-Henriksson H. Insulin action and insulin resistance in human skeletal muscle. Diabetologia 43 (2000) 821-835